Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dehua Zhao, Jing Chen, Mingming Chu & Jisheng Wang. (2019) Prolonged low-dose infusion for gemcitabine: a systematic review. OncoTargets and Therapy 12, pages 4859-4868.
Read now
Read now
Zhi-Yong Wu, Hui-Hong Guan, Ze-Xiao Lin, Hong-Kai Yang, Lan Zhou & Qi-Chun Cai. (2014) Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer. Journal of Chemotherapy 26:5, pages 306-311.
Read now
Read now
Articles from other publishers (20)
Jesse Yu, Qingxin Mu, Simone Perazzolo, James I Griffin, Linxi Zhu, Lisa A McConnachie, Danny D Shen & Rodney JY Ho. (2020) Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules. Pharmaceutical Research 37:10.
Crossref
Crossref
Yang Wang, Gang Wang, Hongxiang Chen, Yixin Sun, Mengchi Sun, Xiaohong Liu, Wang Jian, Zhonggui He & Jin Sun. (2020) A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery. International Journal of Pharmaceutics 573, pages 118718.
Crossref
Crossref
Monica Tang, Julia Chen, David Goldstein, Matthew Links, Sarah LordIan MarschnerRobert J. SimesChee K. Lee. (2019) Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas 48:10, pages 1274-1284.
Crossref
Crossref
Yixin Sun, Dongyang Zhao, Gang Wang, Qikun Jiang, Mengran Guo, Qiming Kan, Zhonggui He & Jin Sun. (2019) A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates. Asian Journal of Pharmaceutical Sciences 14:6, pages 631-639.
Crossref
Crossref
Yilin Sun, Le Zhen, Ying Peng, Jiankun Wang, Fei Fei, Lixiang Aa, Wenjiao Jiang, Xue Pei, Li Lu, Jie Liu, Guangji Wang & Kun Hao. (2018) Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2′, 2′-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. Journal of Chromatography B 1084, pages 4-13.
Crossref
Crossref
L.G. Gorenkova, E.A. Penskaya, S.K. Kravchenko, A.M. Kovrigina, T.N. Moiseeva & A.I. Vorob'ev. (2017) Treatment of Drug-Resistant Mycosis Fungoides and Sezary Syndrome. Clinical oncohematology 10:3, pages 366-371.
Crossref
Crossref
Enaksha R. Wickremsinhe, Lisa B. Lee, Chris A. Schmalz, John Torchia & Kenneth J. Ruterbories. (2013) High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC–MS/MS. Journal of Chromatography B 932, pages 117-122.
Crossref
Crossref
Enaksha Wickremsinhe, Jingqi Bao, Richard Smith, Richard Burton, Shannon Dow & Everett Perkins. (2013) Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure. Pharmaceutics 5:4, pages 261-276.
Crossref
Crossref
Sau Wai Hung, Hardik R. Mody & Rajgopal Govindarajan. (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge. Cancer Letters 320:2, pages 138-149.
Crossref
Crossref
Viljem Kovac, Matjaz Zwitter, Mirjana Rajer, Aleksander Marin, Andrej Debeljak, Uros Smrdel & Martina Vrankar. (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anti-Cancer Drugs 23:2, pages 230-238.
Crossref
Crossref
Matjaz Zwitter, Viljem Kovac, Mirjana Rajer, Martina Vrankar & Uros Smrdel. (2010) Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anti-Cancer Drugs 21:6, pages 662-668.
Crossref
Crossref
David M. Bender, Jingqi Bao, Anne H. Dantzig, William D. Diseroad, Kevin L. Law, Nicholas A. Magnus, Jeffrey A. Peterson, Everett J. Perkins, Yangwei J. Pu, Susan M. Reutzel-Edens, David M. Remick, James J. Starling, Gregory A. Stephenson, Radhe K. Vaid, Deyi Zhang & James R. McCarthy. (2009) Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine. Journal of Medicinal Chemistry 52:22, pages 6958-6961.
Crossref
Crossref
Matjaz Zwitter, Viljem Kovac, Uros Smrdel, Martina Vrankar & Vesna Zadnik. (2009) Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II Clinical Trial. Journal of Thoracic Oncology 4:9, pages 1148-1155.
Crossref
Crossref
J.M. van Riel, G.J. Peters, L.H. Mammatas, R.J. Honeywell, A.C. Laan, R. Ruyter, F.G. van den Berg, G. Giaccone & C.J. van Groeningen. (2009) A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. European Journal of Cancer 45:14, pages 2519-2527.
Crossref
Crossref
Tian-Jie Qin, Xin-Han Zhao, Jun Yun, Ling-Xiao Zhang, Zhi-Ping Ruan & Bo-Rong Pan. (2008) Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World Journal of Gastroenterology 14:33, pages 5210.
Crossref
Crossref
A. Zalatnai. (2007) Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treatment Reviews 33:3, pages 289-298.
Crossref
Crossref
G?ng?r Utkan, Abdullah B?y?k?elik, B?lent Yal??n, Hakan Akbulut, Ahmet Demirkaz?k, Dilek Din?ol, Handan Onur, Deniz G?ren, Umut Mousa, Filiz ?ay ?enler & Fikri ??li. (2006) Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 53:3, pages 367-374.
Crossref
Crossref
Liping Zhang, Vikram Sinha, S. Thomas Forgue, Sophie Callies, Lan Ni, Richard Peck & Sandra R. B. Allerheiligen. (2006) Model-Based Drug Development: The Road to Quantitative Pharmacology. Journal of Pharmacokinetics and Pharmacodynamics 33:3, pages 369-393.
Crossref
Crossref
Stefan von Delius, Christian Lersch, Ewert Schulte-Frohlinde, Martina Mayr, Roland M Schmid & Florian Eckel. (2005) Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5:1.
Crossref
Crossref
M. Zwitter, V. Kovac, U. Smrdel, I. Kocijancic, B. Segedin & M. Vrankar. (2005) Phase I???II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anti-Cancer Drugs 16:10, pages 1129-1134.
Crossref
Crossref